This study aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB41 in combination with SCTB39-1with or without standard therapy in adult patients with advanced malignant solid tumours. This study is an open label, multicentre, dose-escalation and dose-expansion Phase I/II clinical trial.
Voluntarily sign the informed consent form (ICF);
Male or female, ≥ 18 years and ≤ 75 years old;
Survival duration more than 3 months;
ECOG score ≤ 1 point;
Has participated in another clinical study within 4 weeks prior to the first dose;
Has previously received other immunotherapies other than PD-(L)1 inhibitors；
Other malignancies diagnosed within 5 years prior to the enrollment;
Participants with brainstem, meningeal, spinal metastases, or compression; active central nervous system metastases;